NEW YORK (GenomeWeb) – Agilent Technologies and Agendia announced today that they have partnered to develop a next-generation sequencing-based kit version of Agendia’s molecular breast cancer diagnostics.
Under the terms of the deal, the companies will use Agilent’s SureSelect target enrichment system to develop an RNA sequencing kit version of Agendia’s microarray-based MammaPrint 70-gene breast cancer recurrence risk test and its BluePrint breast cancer subtyping assay.
According to the companies, the kit will enable Agendia to develop and perform the two tests as next-generations sequencing assays. The initial phase of the kit’s development is expected to be completed this year, allowing for an early-access rollout in limited European markets.
Additional terms were not disclosed.
“The addition of Agilent’s RNA next-generation sequencing technologies to our current microarray platform will allow us to penetrate international markets where decentralized kit offerings are preferred,” Agendia CEO Mark Straley said in a statement.